RPL13P6: A Promising Drug Target / Biomarker (G100129176)

Target Name: RPL13P6

NCBI ID: G100129176

RPL13P6

Other Name(s): ribosomal protein L13 pseudogene 6 | Ribosomal protein L13 pseudogene 6 | RPL13_5_1409 | RPL13AP4

RPL13P6: A Promising Drug Target / Biomarker

Rpl13p6 is a gene located on chromosome 13q21 that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The Rpl13p6 gene encodes a protein that is involved in the repair of DNA damage, specifically in the DNA double-strand break repair pathway. In recent years, research has identified several potential drug targets and biomarkers associated with the Rpl13p6 gene, and the potential for these targets to be used for therapeutic intervention is under investigation.

The Double-Strand Break Repair Pathway

DNA double-strand breaks are a common type of genetic mutation that can occur during the process of DNA replication. These breaks can result in the loss of genetic information or the formation of a characteristic genetic mutation. The double-strand break repair pathway is a series of steps that occur following a double-strand break in DNA replication, and it is involved in repairing the damage to the double-strand.

The Rpl13p6 gene is involved in the double-strand break repair pathway by encoding a protein that is critical for the repair of DNA double-strand breaks. This protein has been shown to play a role in the formation of double-strand breaks and in the repair of these breaks.

Potential Drug Targets

1. Neutrophil-Induced Cell Death (NICD)

Neutrophil-induced cell death (NICD) is a type of cancer that is caused by the activation of neutrophils, which are a type of white blood cell that play a critical role in fighting off infections. NICD is often treated with antibiotics, but the underlying cause of the disease is not always fully understood.

Research has identified the Rpl13p6 gene as a potential drug target for NICD, and studies have shown that inhibiting the activity of the Rpl13p6 protein can result in a reduction in NICD cell growth. This suggests that the Rpl13p6 protein may be a useful target for the treatment of NICD.

1. neurodegenerative diseases

Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These conditions include Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Research has identified the Rpl13p6 gene as a potential drug target for neurodegenerative diseases, and studies have shown that inhibiting the activity of the Rpl13p6 protein can result in a reduction in the progression of neurodegenerative diseases. This suggests that the Rpl13p6 protein may be a useful target for the treatment of neurodegenerative diseases.

1. Autoimmune disorders

Autoimmune disorders are a group of conditions in which the immune system attacks the body's own tissues or organs, leading to a range of symptoms and conditions. These disorders include rheumatoid arthritis, lupus, and multiple sclerosis.

Research has identified the Rpl13p6 gene as a potential drug target for autoimmune disorders, and studies have shown that inhibiting the activity of the Rpl13p6 protein can result in a reduction in the progression of autoimmune disorders. This suggests that the Rpl13p6 protein may be a useful target for the treatment of autoimmune disorders.

Conclusion

In conclusion, the Rpl13p6 gene has been identified as a potential drug target for NICD, neurodegenerative diseases, and autoimmune disorders. The Rpl13p6 protein is involved in the double-strand break repair pathway and has been shown to play a role in the formation of double-strand breaks and in the repair of these breaks. inhibiting the activity of the Rpl13p6 protein may be a useful

Protein Name: Ribosomal Protein L13 Pseudogene 6

The "RPL13P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets